Reviva Pharmaceuticals Holdings, Inc.
Other OTCTotal Valuation
Reviva Pharmaceuticals Holdings, Inc. carries a market capitalization of 5.90M, placing it among publicly traded companies globally. Its enterprise value stands at -11.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.90M |
| Enterprise Value | -11.50M |
Share Statistics
Reviva Pharmaceuticals Holdings, Inc. currently has 13.11M shares outstanding.
| Shares Outstanding | 13.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.54 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | -0.29 |
| P/OCF Ratio | -0.29 |
Financial Position
Reviva Pharmaceuticals Holdings, Inc. maintains a current ratio of 3.56, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.95, indicating moderate leverage, while an interest coverage ratio of -2,050.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.56 |
| Quick Ratio | 3.35 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -2,050.57 |
Financial Efficiency
| Return on Equity (ROE) | -419.97 |
| Return on Assets (ROA) | -79.46 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 11,700.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Reviva Pharmaceuticals Holdings, Inc.'s stock has declined approximately -95.79832% over the past 52 weeks. The 50-day moving average sits at 0.50, while the 200-day moving average is 1.64.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.79832% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 1.64 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.48M, while operating income came in at -13.48M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.48M |
| Pretax Income | -13.01M |
| Net Income | -13.02M |
| EBITDA | -13.48M |
| EBIT | -13.48M |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
Reviva Pharmaceuticals Holdings, Inc. holds 19.89M in cash and equivalents against 144,093.00 in total debt, resulting in a net debt position of -19.75M. Total book value stands at 15.21M, with working capital of 15.21M providing operational flexibility.
| Cash & Cash Equivalents | 19.89M |
| Total Debt | 144,093.00 |
| Net Debt | -19.75M |
| Equity (Book Value) | 15.21M |
| Book Value Per Share | 1.16 |
| Working Capital | 15.21M |
Cash Flow
Reviva Pharmaceuticals Holdings, Inc. produced -17.30M in operating cash flow over the past twelve months.
| Operating Cash Flow | -17.30M |
| Capital Expenditures | N/A |
| Free Cash Flow | -17.30M |
| FCF Per Share | -2.18 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -325.30 |
| FCF Yield | -345.76 |
Stock Splits
Reviva Pharmaceuticals Holdings, Inc.'s most recent stock split took place on March 9, 2026 with a 20:1 split ratio.
| Last Split Date | 3/9/2026 |
| Split Ratio | 20:1 |
Scores
Reviva Pharmaceuticals Holdings, Inc. posts an Altman Z-Score of -12.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.97 |